Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Faron Pharmaceuticals Oy

www.faronpharmaceuticals.com

Latest From Faron Pharmaceuticals Oy

Can Fresh INTEREST Breathe New Life Into Faron's Traumakine?

Faron's ARDS drug looked doomed after the INTEREST study earlier this year but the Finnish group claims that a DNA analysis has identified some patients for whom Traumakine treatment could potentially be effective.

Respiratory Clinical Trials

Pipeline Watch: Top-Line Phase III Results For Esketamine, ALKS-5461 And Quizartinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Pipeline Watch

Faron’s Traumakine Flops In Phase III

Faron Pharmaceuticals’ stock has plummeted more than 80% on the news its lead drug failed in a Phase III trial – the company will now shift its focus to an investigational cancer therapy, but this is yet to enter the clinic.

Business Strategies Research and Development Strategies

Faron CEO Markku Jalkanen Outlines Commercial Ambitions

The US FDA approves IND application of Faron’s lead Traumakine program for acute respiratory distress syndrome as company prepares for pivotal Phase III data readout this spring. The CEO outlines company’s Traumakine commercialization plans and provides update on its Clevegen ambitions.

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Finland
  • Company Type
  • Midsize European
  • Parent & Subsidiaries
  • Faron Pharmaceuticals Oy
  • Senior Management
  • Markku Jalkanen, PhD, CEO & founder
    Yrjo Wichmann, CFO
    Ilse Piipo, MD, CMO, VP Drug Development
    Mikael Maksimow, PhD, VP, Ops
  • Contact Info
  • Faron Pharmaceuticals Oy
    Phone: 2 469 5151
    Joukahaisenkatu 6, Intelligate
    TURKU, FIN-20520
    Finland
Advertisement
Advertisement
UsernamePublicRestriction

Register